
Extendicare Inc
TSX:EXE

Intrinsic Value
The intrinsic value of one
EXE
stock under the Base Case scenario is
19.32
CAD.
Compared to the current market price of 13.7 CAD,
Extendicare Inc
is
Undervalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Extendicare Inc
Loading...
Fundamental Analysis


Revenue & Expenses Breakdown
Extendicare Inc
Balance Sheet Decomposition
Extendicare Inc
Current Assets | 231.4m |
Cash & Short-Term Investments | 109.5m |
Receivables | 91.2m |
Other Current Assets | 30.7m |
Non-Current Assets | 482.2m |
Long-Term Investments | 24.2m |
PP&E | 304.9m |
Intangibles | 119.2m |
Other Non-Current Assets | 33.9m |
Free Cash Flow Analysis
Extendicare Inc
CAD | |
Free Cash Flow | CAD |
Earnings Waterfall
Extendicare Inc
Revenue
|
1.5B
CAD
|
Cost of Revenue
|
-1.3B
CAD
|
Gross Profit
|
207m
CAD
|
Operating Expenses
|
-90.4m
CAD
|
Operating Income
|
116.6m
CAD
|
Other Expenses
|
-39.4m
CAD
|
Net Income
|
77.1m
CAD
|
EXE Profitability Score
Profitability Due Diligence
Extendicare Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.

Score
Extendicare Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
EXE Solvency Score
Solvency Due Diligence
Extendicare Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Score
Extendicare Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EXE Price Targets Summary
Extendicare Inc
According to Wall Street analysts, the average 1-year price target for
EXE
is 16.4 CAD
with a low forecast of 14.65 CAD and a high forecast of 21 CAD.
Dividends
Current shareholder yield for EXE is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
EXE
stock under the Base Case scenario is
19.32
CAD.
Compared to the current market price of 13.7 CAD,
Extendicare Inc
is
Undervalued by 29%.